Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms.

Brennan SK, Wang Q, Tressler R, Harley C, Go N, Bassett E, Huff CA, Jones RJ, Matsui W.

PLoS One. 2010 Sep 1;5(9). pii: e12487. doi: 10.1371/journal.pone.0012487.

2.

The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.

Joseph I, Tressler R, Bassett E, Harley C, Buseman CM, Pattamatta P, Wright WE, Shay JW, Go NF.

Cancer Res. 2010 Nov 15;70(22):9494-504. doi: 10.1158/0008-5472.CAN-10-0233. Epub 2010 Nov 9.

3.

The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.

Koziel JE, Herbert BS.

Breast Cancer Res Treat. 2015 Feb;149(3):607-18. doi: 10.1007/s10549-015-3270-1. Epub 2015 Jan 28.

4.

Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition.

Castelo-Branco P, Zhang C, Lipman T, Fujitani M, Hansford L, Clarke I, Harley CB, Tressler R, Malkin D, Walker E, Kaplan DR, Dirks P, Tabori U.

Clin Cancer Res. 2011 Jan 1;17(1):111-21. doi: 10.1158/1078-0432.CCR-10-2075.

5.

The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.

Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, Mickey BE, Wright WE, Shay JW, Bachoo RM.

Clin Cancer Res. 2010 Jan 1;16(1):154-63. doi: 10.1158/1078-0432.CCR-09-2850.

6.

Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.

Frink RE, Peyton M, Schiller JH, Gazdar AF, Shay JW, Minna JD.

Oncotarget. 2016 May 31;7(22):31639-51. doi: 10.18632/oncotarget.9335.

7.

Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.

Barszczyk M, Buczkowicz P, Castelo-Branco P, Mack SC, Ramaswamy V, Mangerel J, Agnihotri S, Remke M, Golbourn B, Pajovic S, Elizabeth C, Yu M, Luu B, Morrison A, Adamski J, Nethery-Brokx K, Li XN, Van Meter T, Dirks PB, Rutka JT, Taylor MD, Tabori U, Hawkins C.

Acta Neuropathol. 2014 Dec;128(6):863-77. doi: 10.1007/s00401-014-1327-6. Epub 2014 Aug 6.

8.

Identification of CD133(-)/telomerase(low) progenitor cells in glioblastoma-derived cancer stem cell lines.

Beier F, Beier CP, Aschenbrenner I, Hildebrandt GC, Brümmendorf TH, Beier D.

Cell Mol Neurobiol. 2011 Apr;31(3):337-43. doi: 10.1007/s10571-010-9627-4. Epub 2010 Nov 17.

PMID:
21082235
9.

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA, Jones RJ.

Cancer Res. 2008 Jan 1;68(1):190-7. doi: 10.1158/0008-5472.CAN-07-3096.

10.

Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.

Shammas MA, Shmookler Reis RJ, Akiyama M, Koley H, Chauhan D, Hideshima T, Goyal RK, Hurley LH, Anderson KC, Munshi NC.

Mol Cancer Ther. 2003 Sep;2(9):825-33.

11.

Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival.

Reghunathan R, Bi C, Liu SC, Loong KT, Chung TH, Huang G, Chng WJ.

Oncotarget. 2013 Aug;4(8):1230-40.

12.

Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer.

Serrano D, Bleau AM, Fernandez-Garcia I, Fernandez-Marcelo T, Iniesta P, Ortiz-de-Solorzano C, Calvo A.

Mol Cancer. 2011 Aug 9;10:96. doi: 10.1186/1476-4598-10-96.

13.

Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.

Hu Y, Bobb D, Lu Y, He J, Dome JS.

Cancer Genet. 2014 Sep;207(9):403-11. doi: 10.1016/j.cancergen.2014.09.002. Epub 2014 Sep 16.

PMID:
25441685
14.

Expression profile of telomere-associated genes in multiple myeloma.

Díaz de la Guardia R, Catalina P, Panero J, Elosua C, Pulgarin A, López MB, Ayllón V, Ligero G, Slavutsky I, Leone PE.

J Cell Mol Med. 2012 Dec;16(12):3009-21. doi: 10.1111/j.1582-4934.2012.01628.x.

15.

Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.

Shammas MA, Shmookler Reis RJ, Li C, Koley H, Hurley LH, Anderson KC, Munshi NC.

Clin Cancer Res. 2004 Jan 15;10(2):770-6.

16.

Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.

Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC.

Cancer Res. 2003 Oct 1;63(19):6187-94.

17.

Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.

Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, Blotta S, Protopopov A, Mitsiades C, Batchu RB, Anderson KC, Chin A, Gryaznov S, Munshi NC.

Leukemia. 2008 Jul;22(7):1410-8. doi: 10.1038/leu.2008.81. Epub 2008 May 1.

18.

Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.

Wu X, Smavadati S, Nordfjäll K, Karlsson K, Qvarnström F, Simonsson M, Bergqvist M, Gryaznov S, Ekman S, Paulsson-Karlsson Y.

Biochim Biophys Acta. 2012 Dec;1823(12):2130-5. doi: 10.1016/j.bbamcr.2012.08.003. Epub 2012 Aug 11.

19.

Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells.

Chapman EJ, Kelly G, Knowles MA.

Mol Cancer Res. 2008 Jul;6(7):1154-68. doi: 10.1158/1541-7786.MCR-07-2168.

20.

Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression.

Beck S, Jin X, Sohn YW, Kim JK, Kim SH, Yin J, Pian X, Kim SC, Nam DH, Choi YJ, Kim H.

Mol Cells. 2011 Jan;31(1):9-15. doi: 10.1007/s10059-011-0008-8. Epub 2010 Dec 24.

Supplemental Content

Support Center